Statement of Principles concerning tardive dyskinesia (Reasonable Hypothesis) (No. 78 of 2023)

The instrument applies to persons who lodge claims within the statutory ambit specified in s 4: claims “to which section 120A of the VEA or section 338 of the MRCA applies” (s 4). The Schedule’s definition of “relevant service” clarifies the range of service types covered,operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1). Consequently the instrument targets veterans, members of Peacekeeping Forces, and members of the Forces covered by those Acts, insofar as they seek benefits or findings under the cited claim provisions.

Who decides: the Repatriation Medical Authority made the SoP (s 3); the instrument’s language indicates it is intended to operate as the evidentiary foundation in the assessment of relevant claims (s 4). The instrument itself does not name the administrative decision‑maker that applies the SoP in individual claims; however, by its terms it applies to claims under specific provisions of the VEA and MRCA (s 4). The RMA’s stated view that “there is sound medical‑scientific evidence” underpins the instrument (s 7).

Who bears burdens and obligations: the instrument imposes no direct criminal, civil or pecuniary penalties in its text. Instead, it sets out the facts that must exist for a reasonable hypothesis to be raised in a claims context (s 8). Practically, persons seeking to rely on the SoP will need to establish the presence and service‑relationship of the listed factors (s 8, s 9). Medical practitioners and record‑keepers supplying evidence for claims will be affected in that clinical detail about medication types, duration, timing of onset and withdrawal, and availability of clinical management may be integral to meeting the stated factors (see s 6, s 8).

Indirect stakeholders: where a listed factor refers to an injury or disease covered by another SoP, that other SoP’s terms apply (s 10). The Schedule’s definitions of DSM‑5‑TR and terminal event shape clinical characterisation (Schedule 1).

The instrument does not create freestanding statutory duties of conduct or express rights of payment or compensation. Its operative legal role is to specify the medical criteria and factual factors that constitute the threshold for raising a reasonable hypothesis connecting tardive dyskinesia or death from it to relevant service in claims to which it applies (s 6, s 8, s 4).

Duty to establish factors: for a claimant to invoke the SoP, at least one of the factors listed in section 8 must exist and must be related to the person’s relevant service (s 8; s 9(1)). The listed factors create evidentiary benchmarks: for example, s 8(1) requires documentary or clinical support that an antipsychotic was taken for the prescribed minimum continuous period (three months if under 60, one month if 60 or over) and that onset or worsening occurred during use or within the specific withdrawal windows (s 8(1), s 6(2)(a)(iii)-(iv)). Similarly, s 8(2) sets exposure and timing thresholds for specified antiemetic drugs and buspirone.

Limitation and scope rules: subsection 9(2) limits the operation of s 8(3) (anticholinergic medications that cannot be ceased or substituted) and s 8(4) (inability to obtain appropriate clinical management) to circumstances where the person’s tardive dyskinesia was suffered or contracted before or during relevant service, but did not arise out of service (s 9(2)). That defines the SoP’s application as either material contribution or aggravation in pre‑existing disease scenarios (s 9(2)).

Cross‑application: where a factor in s 8 refers to another injury or disease covered by another SoP, that other SoP’s factors apply “in accordance with the terms of that Statement of Principles as in force from time to time” (s 10). This creates a structural duty for assessing agencies to consult and apply other SoPs when the factor points to a different, SoP‑covered condition.

RMA’s view and evidentiary basis: section 7 formally records the RMA’s medical‑scientific rationale for determining the SoP: that sound medical‑scientific evidence indicates the condition and death from it can be related to relevant service (s 7). That statement is the RMA’s claimed basis, not a procedural right or duty; it is the authority the RMA cites for setting the SoP.

Rights implicit in application: the practical consequence is that claimants whose cases meet a listed factor that is service‑related will have the statutory threshold for a reasonable hypothesis met for the purposes of claims covered by s 120A VEA or s 338 MRCA (s 4, s 8, s 9). The instrument does not itself adjudicate entitlement or award benefits; it supplies the causation framework used in the statutory claims process.

The Statement of Principles contains no offence provisions, monetary penalties, or express enforcement mechanisms. It is an evidentiary instrument that sets factors and definitions to be applied in claim assessments under parts of the VEA and the MRCA (s 3, s 4). There is therefore no direct enforcement regime in the text of the instrument; compliance and enforcement occur indirectly through the decision‑making and review processes established by the VEA and MRCA and their administrative mechanisms, which are outside the instrument’s text.

Consequences in claims assessment: failure to establish one of the s 8 factors, or failure to show the factor is related to relevant service as required by s 9, will affect a claimant’s ability to have a reasonable hypothesis raised under this SoP. That evidentiary consequence will influence administrative outcomes in claims under the specified provisions (s 4, s 8, s 9). The instrument itself does not prescribe remedies, sanctions, or review pathways; those are governed by the underlying statutes and administrative law.

No criminal or civil penalty provisions: the SoP does not purport to create new criminal liabilities, civil damages causes of action, or quarantine enforcement measures. It is limited to medical characterisation and causal factors for claims purposes. The Schedule’s definitions and the RMA’s stated evidentiary basis (s 7 and Schedule 1) frame the SoP’s application but do not in themselves trigger penalties.

Administrative discretion and possible enforcement implications: because decision‑makers applying the SoP will have to determine whether the factual factors are present and service‑related, the instrument creates space for administrative fact‑finding and exercise of discretion in individual claims. The instrument does not set standards for review, burden of proof, or how conflicting medical opinions are to be weighed; those procedural matters remain governed by the VEA, MRCA and general administrative law processes, not by this SoP text.

Statutory provenance and application: the instrument is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (s 3). It expressly applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies (s 4). Thus its practical effect is limited to the claims framework established under those Acts; it does not operate as a freestanding statute outside that claims context.

Cross‑SoP interaction: section 10 provides an explicit mechanism for interaction with other Statements of Principles. If a factor listed in s 8 refers to an injury or disease already the subject of another SoP made under subsection 196B(2) of the VEA, then “the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time” (s 10). This means that where a listed factor implicates a different, SoP‑covered condition, decision‑makers must apply the other SoP’s terms as the operative framework for that aspect of causation.

Definitions and classification regimes: subsection 6(3)-(4) notes that although tardive dyskinesia corresponds to ICD‑10‑AM code G24.01, the meaning in this instrument is the statutory definition at subsection 6(2). The instrument thus uses DSM‑5‑TR as the source for medical criteria (Schedule 1), while acknowledging ICD classification but subordinating it to the statutory textual definition for claims purposes. This produces an interaction between international diagnostic nomenclature and the instrument’s statutory definition: the ICD code is informative but not definitive for the SoP’s legal operation (s 6(3)-(4)).

Relationship with the VEA and MRCA: because the instrument applies to claims under specific VEA and MRCA provisions (s 4), its practical operation is interconnected with the eligibility, entitlement, evidentiary and review rules of those Acts. The SoP sets a causation threshold; entitlement, compensation, rehabilitation or other legal consequences depend on how the VEA and MRCA procedures and decision‑makers apply the SoP in individual cases. The instrument itself does not modify the substantive entitlements or procedural rules in those Acts.

Administrative law overlay: the instrument creates factual predicates that administrative decision‑makers will assess. Challenges to outcomes that rely on the SoP will engage the decision‑making and review paths provided by the VEA and MRCA and general administrative law, but the instrument does not specify those review mechanisms. The RMA’s stated medical basis (s 7) will likely be invoked as the expert determination underpinning the SoP where questions of interpretation arise, but the SoP’s text, not extrinsic materials, governs its immediate application.

This SoP is identified in the instrument as “No. 78 of 2023” and the instrument records that it was dated 25 August 2023 and commences on 26 September 2023 (s 1; s 2). The instrument contains no internal amendments, savings, transitional or sunset clauses. It does not refer to prior versions of a tardive dyskinesia SoP nor to supersession of an earlier instrument; no earlier or amending instruments are mentioned in the text supplied.

Procedural basis for change: the instrument is made under subsection 196B(2) of the VEA (s 3). That subsection is the statutory head of power referenced for making Statements of Principles; the instrument therefore derives its amendment or replacement pathway from the enabling provision in the VEA, though the enabling provision’s mechanics are not reproduced within this statement. This SoP itself does not set periodic review dates, nor does it specify the RMA’s internal review process or triggers for amendment; such processes, if any, would be external to the instrument text.

Status and currency: the instrument’s commencement date indicates when the SoP becomes operative for claims (s 2). The instrument’s section 10 contemplates that other SoPs may be in force “from time to time,” implicitly recognising that SoPs are modifiable; however, the instrument does not itself record any subsequent amendments or supersessions. Any later modification, revocation, or replacement would be the subject of a separate instrument made under the same statutory power.

Record‑keeping and citation: for legal and administrative purposes, practitioners should cite the instrument by its name and number (“Statement of Principles concerning tardive dyskinesia (Reasonable Hypothesis) (No. 78 of 2023)”), and attach the commencement date (26 September 2023) when relying on or comparing SoPs across time (s 1; s 2). The Schedule and internal subsection numbering are the operative references for parsing definitions and factors.

The instrument’s text contains no references to judicial or tribunal decisions, and it does not list any litigation history. It records the RMA’s medical‑scientific view as the basis for the SoP (s 7) but does not identify any cases, appeals, administrative findings or precedent that led to its making. The Schedule and the body of the instrument likewise contain no citations to case law or administrative determinations.

Because the instrument is a Statement of Principles made under subsection 196B(2) of the VEA, disputes about the application of this SoP to particular claims would arise within the statutory claim and review processes established under the VEA and the MRCA, and in the ordinary course could be subject to merits review or judicial review pathways provided by those regimes. The instrument itself does not catalogue or report any such disputes or outcomes.

Practitioners seeking authority or interpretive guidance will therefore need to rely on the SoP’s text (s 6-10, Schedule 1) and any applicable decisions made after its commencement. The SoP’s statement of the RMA’s view that there is “sound medical‑scientific evidence” (s 7) is the RMA’s explanatory position recorded in the instrument; the text does not furnish supporting studies, expert reports, or litigation outcomes as source citations.

Precision of timing and duration thresholds: the SoP contains detailed, non‑symmetrical timing rules that are decisive for whether a factor in s 8(1)-(2) exists. For antipsychotics the minimum continuous exposure differs by age (three months if under 60, one month if 60 or older) (s 8(1); s 6(2)(a)(iii)). For onset/withdrawal, the SoP requires movements to be present for at least four weeks and to develop during medication use or within four weeks of withdrawal from an oral agent, or within eight weeks after withdrawal of a long‑acting injectable agent (s 6(2)(a)(ii), (iv)). Small differences in recorded start/stop dates, or uncertainty about the form of the agent (oral v long‑acting injectable), can therefore be decisive.

Drug lists and scope: s 8(2) specifies a narrow list of antiemetic drugs,metoclopramide, domperidone, droperidol, prochlorperazine,and single anxiety drug buspirone. The medicolegal significance of other dopamine‑blocking or dopamine‑modulating agents is not listed; absent explicit inclusion, such agents do not automatically satisfy s 8(2). Similarly, s 6(2)(a)(i) ties the core definition to medications that block postsynaptic dopamine receptors; whether a particular drug’s mechanism of action fits that description is a factual and potentially contested question.

Exclusions are express and categorical: several neurological diseases and medication‑induced movement disorders are excluded by s 6(2)(b). A claimant’s presentation that overlaps with excluded diagnoses may therefore be outside the SoP’s scope even if tardive‑style movements are present, unless the clinical evidence isolates tardive dyskinesia as defined in s 6(2).

Anticholinergics and clinical management factors operate in limited circumstances: s 8(3)-(4) are available only as factors for material contribution or aggravation where tardive dyskinesia was suffered or contracted before or during service but did not arise out of service (s 9(2)). In other words, those factors do not supply a pathway to raise a reasonable hypothesis for tardive dyskinesia that itself arose out of service; they are confined to aggravation or material contribution to pre‑existing disease (s 9(2)).

ICD code note: subsection 6(3) affirms that although tardive dyskinesia is associated with ICD‑10‑AM code G24.01, the SoP’s operative meaning is the statutory definition at subsection 6(2). Practitioners should not assume that a coding entry alone satisfies the SoP; the textual requirements in s 6(2) control.

Death claims and terminal events: s 6(5) extends the SoP to include death from a terminal event or condition contributed to by tardive dyskinesia. The Schedule gives examples of terminal events (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function), but “terminal event” is not exhaustively defined; establishing that the terminal event was contributed to by tardive dyskinesia remains a factual question grounded in medical evidence (s 6(5); Schedule 1).

Cross‑SoP dependencies: where a factor refers to another SoP‑covered condition, the other SoP’s terms apply “as in force from time to time” (s 10). That creates a dependency risk: when the linked SoP is amended, the application of the current tardive dyskinesia SoP might yield different practical results. Practitioners must check the current wording of any cross‑referenced SoPs at the time of claim adjudication.

Burden of proof and administrative processes not specified: the SoP sets the factors that raise a reasonable hypothesis, but it does not state who bears the evidentiary burden or how competing medical opinions are to be resolved. Those procedural issues sit in the VEA/MRCA frameworks and administrative law practice rather than in the SoP text (s 4).

Frame compliance in terms of the SoP’s elements. The instrument requires that at least one s 8 factor exists and that the factor be related to relevant service (s 8; s 9(1)). For claim preparation and adjudication, evidence should therefore be assembled and framed to correspond tightly to the textual elements the SoP requires.

1. Establish the diagnosis against the SoP definition

• Use clinical records that document the presence of abnormal, involuntary movements of the tongue, jaw, trunk or extremities, and their persistence for at least four weeks, as required by s 6(2)(a)(i)-(ii).
• Ensure that the clinical characterisation is consistent with the DSM‑5‑TR‑derived criteria the SoP adopts (Schedule 1; s 6(2)) rather than relying solely on an ICD code (s 6(3)-(4)).

2. Show the requisite medication exposure and timing

• For s 8(1) antipsychotic exposure, produce records confirming agent(s) taken, formulation (oral v long‑acting injectable), continuous duration (three months if under 60, one month if 60 or over) and timing of symptom onset or worsening relative to use or withdrawal (s 8(1); s 6(2)(a)(iii)-(iv)).
• For s 8(2) antiemetic/buspirone exposure, document drug identity (metoclopramide, domperidone, droperidol, prochlorperazine, buspirone), continuous duration thresholds and timing relative to onset (s 8(2)).

3. If relying on s 8(3) or s 8(4), establish the limited scope conditions

• s 8(3) (anticholinergic use that could not be ceased/substituted) and s 8(4) (inability to obtain appropriate clinical management) apply only where the tardive dyskinesia was suffered or contracted before or during service and did not arise out of service (s 9(2)). Evidence must therefore show the pre‑existing nature of the condition and why the anticholinergic could not be changed or why appropriate management was unavailable at the time of clinical worsening.

4. Demonstrate service relationship

• The SoP requires the factor to be related to the person’s relevant service (s 9(1)). Provide service records and chronology that tie the exposure or clinical circumstances to the relevant service periods as defined in Schedule 1 (operational, peacekeeping, hazardous, British nuclear test defence service, warlike or non‑warlike service).

5. Where death is the claim subject

• For claims involving death, show that the terminal event (examples listed in Schedule 1) was contributed to by the person’s tardive dyskinesia (s 6(5)). Medical opinion linking the movement disorder to the proximate or ultimate cause of death will be central.

6. Check cross‑references to other SoPs

• If a factor in s 8 refers to another injury or disease that is covered by a different SoP, identify and apply the current terms of that SoP (s 10). Confirm whether any amendments to the linked SoP are in force at the relevant time.

7. Documentation and specificity

• Because the SoP’s thresholds turn on discrete factual criteria (drug identity, duration, age thresholds, formulation, withdrawal windows, inability to cease medications, availability of management), ensure chronological medical and pharmaceutical records are as precise as possible (s 6; s 8). Clinical opinions should map findings directly to the statutory language.

8. Be cautious about excluded diagnoses

• Where clinical features or records indicate alternative causes listed in s 6(2)(b) (medication‑induced parkinsonism, acute dystonia, acute akathisia, l‑dopa/bromocriptine‑related dyskinesia, spontaneous dyskinesia, Huntington disease, Wilson disease, Sydenham chorea, systemic lupus erythematosus, heavy metal poisoning), show why tardive dyskinesia as defined still applies, or accept that the SoP will not cover such presentations.

9. Record‑keeping and contemporaneous notes

• Given the emphasis on precise temporal relationships and treatment histories, contemporaneous clinical notes, pharmacy dispensing records, hospital discharge summaries, and aged care or GP records will be the primary source evidence that aligns with the SoP’s factors (s 6; s 8).

10. Review the RMA’s stated basis if required

• The RMA notes that its view is that sound medical‑scientific evidence supports a link between tardive dyskinesia and relevant service (s 7). Where detailed interpretation issues arise, consider eliciting medical opinions that frame conclusions against the SoP’s criteria and the RMA’s stated basis.

In short, to comply with the SoP you must show (i) the statutory definition of tardive dyskinesia is met (s 6), (ii) at least one s 8 factor exists with the precise elements the instrument lists, and (iii) that factor is related to relevant service as defined in the Schedule (s 8; s 9; Schedule 1). The SoP does not specify procedural burdens of proof or review pathways; those remain functions of the VEA/MRCA claim processes referenced in s 4.